Using active surveillance for Gleason 7 (3+4) prostate cancer: A narrative review

Can Urol Assoc J. 2023 Dec 21. doi: 10.5489/cuaj.8539. Online ahead of print.ABSTRACTThe interest in broadening the application of active surveillance (AS) has been increasing, encompassing patients who may not strictly adhere to the conventional criteria for low-risk prostate cancer (PCa), particularly those diagnosed with small-volume Gleason grade group 2 disease. Nonetheless, accurately identifying individuals with low-intermediate risk PCa who can safely undergo AS without facing disease progression remains a challenge.This review aims to delve into the progression of this evolving trend specifically within this cohort of men, while also examining strategies aimed at minimizing irreversible disease advancement. Additionally, we address the criteria for patient selection, recommended followup schedules, and the indicators prompting intervention.PMID:38381936 | DOI:10.5489/cuaj.8539
Source: Canadian Urological Association Journal - Category: Urology & Nephrology Authors: Source Type: research